RE: Re:IPF8 Oct 2020 20:38
Hi Olderbutwiser, my theory is that NXP004 is a co-crystal of pirfenidone as its patent is expiring.
Both of the current therapies can have severe side-effects so my inkling is they are looking to improve on this front with pre-clinical trials mooted.
Don'f forget Pirfenidone was used in NXP002 trials so maybe JH did a little experimentation while she had access to it.
Now this current RNS - Additional pre-clinical work for evaluation of the benefits of NXP002 in combination with existing marketed products in the treatment of IPF (Idiopathic Pulmonary Fibrosis, a serious lung disease), targeting the existing global IPF market valued at approximately US$2 billion per annum.
What if they now are thinking of dual therapy ****tail of NXP002 and NXP004 to combat pulmonary fibrosis in conjunction. Obviously a lot of safety trials will be required but with COVID hospitalisations getting worse, you would think a medium to big pharma is interested in taking both off our hands for a small upfront payment say £20m-30m, with only simpler phased trials than starting afresh.
This is ALL in MY BIG FAT OPINION and maybe a dream i dreamed, and soup will probably find holes in this :)